Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Incyte Corporation (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 27,906,056
  • Shares Outstanding, K 204,770
  • Annual Sales, $ 1,106 M
  • Annual Income, $ 104,220 K
  • 36-Month Beta 0.84
  • Price/Sales 25.12
  • Price/Cash Flow 145.10
  • Price/Book 28.73

Price Performance

See More
Period Period Low Period High Performance
1-Month
115.20 +17.24%
on 06/12/17
137.30 -1.63%
on 06/26/17
+0.68 (+0.51%)
since 05/26/17
3-Month
114.03 +18.44%
on 05/15/17
144.32 -6.42%
on 04/05/17
-4.58 (-3.28%)
since 03/24/17
52-Week
71.75 +88.24%
on 06/27/16
153.15 -11.81%
on 03/15/17
+58.08 (+75.45%)
since 06/24/16

Most Recent Stories

More News
Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger

This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in...

CNCR : 23.99 (+1.30%)
BLUE : 111.05 (-0.85%)
MRK : 66.01 (-0.23%)
INCY : 134.93 (-0.99%)
KITE : 100.54 (-0.12%)
PFE : 34.10 (-0.20%)
Today's Research Reports on Stocks to Watch: Amgen and Incyte

NEW YORK, NY / ACCESSWIRE / June 22, 2017 / It wasn't quite clear why Incyte Corporation shares exploded on Wednesday to close in the green up nearly 8%, especially as there was no news from the company....

INCY : 134.93 (-0.99%)
AMGN : 173.93 (+0.83%)
4 Stocks & ETFs to Buy on Clovis' Positive Drug Data

Clovis Oncology clinical trial data has given a boost to the biotech sector and put these stocks and ETFs in focus.

BBC : 25.31 (+0.84%)
CLDX : 2.64 (+0.76%)
CNCR : 23.99 (+1.30%)
IBB : 320.25 (-0.15%)
LABU : 71.27 (-0.88%)
KITE : 100.54 (-0.12%)
CGIX : 4.05 (+5.19%)
BBP : 41.25 (-0.24%)
SBIO : 28.75 (+0.59%)
UBIO : 35.30 (-0.14%)
INCY : 134.93 (-0.99%)
CLVS : 93.18 (-1.92%)
BIB : 57.23 (+0.07%)
XBI : 80.21 (-0.12%)
Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More

The oncology space has always been keenly watched by investors interested in the pharma/biotech sector.

CELG : 133.66 (-0.48%)
BLUE : 111.05 (-0.85%)
MRK : 66.01 (-0.23%)
PBYI : 88.65 (+1.31%)
INCY : 134.93 (-0.99%)
CLVS : 93.18 (-1.92%)
KITE : 100.54 (-0.12%)
AMGN : 173.93 (+0.83%)
PFE : 34.10 (-0.20%)
4 Stocks & ETFs to Buy on Clovis' Positive Drug Data

Clovis Oncology clinical trial data has given a boost to the biotech sector and put these stocks and ETFs in focus.

BBC : 25.31 (+0.84%)
CLDX : 2.64 (+0.76%)
CNCR : 23.99 (+1.30%)
IBB : 320.25 (-0.15%)
LABU : 71.27 (-0.88%)
KITE : 100.54 (-0.12%)
CGIX : 4.05 (+5.19%)
BBP : 41.25 (-0.24%)
SBIO : 28.75 (+0.59%)
UBIO : 35.30 (-0.14%)
INCY : 134.93 (-0.99%)
CLVS : 93.18 (-1.92%)
BIB : 57.23 (+0.07%)
XBI : 80.21 (-0.12%)
Look for Shares of Incyte to Potentially Pullback after Yesterday's 2.62% Rise

Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $118.38 to a high of $121.62. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $121.50...

INCY : 134.93 (-0.99%)
Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data on safety and long-term efficacy from the Olumiant® (baricitinib) clinical trials will be presented...

LLY : 84.08 (+0.23%)
INCY : 134.93 (-0.99%)
Incyte (INCY) Up 3.4% Since Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INCY : 134.93 (-0.99%)
Incyte to Present at Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June:

INCY : 134.93 (-0.99%)
Incyte Provides Updated Data on Cancer Combination Therapies

Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of...

AZN : 35.10 (+0.09%)
MRK : 66.01 (-0.23%)
INCY : 134.93 (-0.99%)
BMY : 57.14 (+0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of...

See More

Support & Resistance

2nd Resistance Point 138.69
1st Resistance Point 137.48
Last Price 134.93
1st Support Level 134.45
2nd Support Level 132.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.